Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 13/20 | 0.48 |
| ▸ | PPARA | Q07869 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.42 |
| ▸ | IDH1 | O75874 | 4/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29516311 | 0.90 | PPARA (0.43) | PPARAIDH1 | |
| SCHEMBL1915787 | 0.89 | PPARA (0.42) | CHRM1PPARAIDH1 | |
| SCHEMBL1915789 | 0.89 | PPARA (0.42) | CHRM1PPARAIDH1 | |
| SCHEMBL8555423 | 0.89 | GAA (0.46) | CHRM1PPARAIDH1 | |
| SCHEMBL8555074 | 0.87 | PPARA (0.47) | CHRM1PPARAIDH1 | |
| SCHEMBL18152511 | 0.87 | PPARA (0.39) | CHRM1PPARA | |
| SCHEMBL18152514 | 0.87 | PPARA (0.39) | CHRM1PPARA | |
| SCHEMBL6421893 | 0.86 | CYP2C19 (0.46) | CHRM1PPARAIDH1 | |
| SCHEMBL5160821 | 0.86 | CYP2C19 (0.46) | CHRM1PPARAIDH1 | |
| SCHEMBL7350489 | 0.86 | CYP2C19 (0.46) | CHRM1PPARAIDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014016766-A1 | GUANIDINE DERIVATIVES AS TRPC MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2014-01-30 | — | — | WO | disclosed |
| US-20120149718-A1 | Amido Compounds | BROTHERTON-PLEISS CHRISTINE E (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149718-A1 | Amido Compounds | P2RX7, P2RX3, P2RX2 | CHRM1 755/4885PPARA 399/4885EPHX1 1013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.